Previous close | 32.25 |
Open | 32.25 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 180.00 |
Expiry date | 2024-10-18 |
Day's range | 32.25 - 32.25 |
Contract range | N/A |
Volume | |
Open interest | 26 |
In the last year, many Moderna, Inc. ( NASDAQ:MRNA ) insiders sold a substantial stake in the company which may have...
Moderna stock is trading sideways despite a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca